Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the publication of clinical findings for vaginally-administered ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA

Dare Bioscience (DARE) Halted on LUDPMarch 18, 2019 10:06 AM Daré Bioscience Announces Publication of Positive Clinical Findings for Vaginal Administration of Tamoxifen for the Treatment of VVAMarch 18, 2019 8:00 AM